Related Experiment Video

Updated: Jul 3, 2026

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

Active intravenous drug use during chronic hepatitis C therapy does not reduce sustained virological response rates

P Bruggmann1, L Falcato, S Dober

  • 1ARUD Zurich, Association for Risk Reduction in the Use of Drugs, Zurich, Switzerland. p.bruggmann@arud-zh.ch

Journal of Viral Hepatitis
|July 19, 2008
PubMed

Insights

Treating chronic hepatitis C in active intravenous drug users (IDUs) is often deferred, but this study shows no significant difference in sustained virological response (SVR) rates. Adherent IDUs achieve comparable treatment success to non-IDUs, challenging current guidelines.

Area of Science:

  • Hepatology
  • Infectious Diseases
  • Public Health

Background:

  • Chronic hepatitis C treatment guidelines often recommend deferring therapy for active intravenous drug users (IDUs).
  • Clinical practice and international guidelines reflect a reluctance to treat this population due to perceived risks.
  • Limited evidence exists to unequivocally support delaying hepatitis C treatment for active IDUs.

Purpose of the Study:

  • To retrospectively analyze the direct impact of active intravenous drug use on the efficacy of anti-hepatitis C virus (HCV) therapy.
  • To compare treatment outcomes, specifically sustained virological response (SVR), between active IDUs and non-IDUs.
  • To evaluate the influence of active IV drug use on treatment success in chronic hepatitis C patients.

Main Methods:

  • Retrospective analysis of 500 chronic hepatitis C patients from the Swiss Hepatitis C Cohort Study.
  • Inclusion criteria required serum HCV RNA testing 6 months post-treatment and documentation of drug use status during therapy.
  • Patients were categorized into active IDUs (n=199) and controls (n=301).

Main Results:

  • Adherence to antiviral therapy (≥80% cumulative dose) was similar between IDUs (66.0%) and controls (60.5%).
  • The overall sustained virological response (SVR) rate was 63.6%.
  • Active IDUs achieved an SVR rate of 69.3%, which was not statistically different from controls (59.8%).
  • Multivariate analysis indicated no significant negative influence of active IV drug use on treatment success.

Conclusions:

  • Active intravenous drug use does not appear to directly influence the efficacy of anti-HCV therapy in adherent patients.
  • The study challenges the current practice of deferring hepatitis C treatment for active IDUs.
  • Findings suggest that adherence, rather than active drug use, is a key factor in achieving SVR.
Abstract

More Related Videos

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions01:24

Drug Accumulation During Multiple Dosing: Intermittent IV Infusions

Intermittent intravenous (IV) infusion is a method of drug administration where medications are delivered over short infusion periods followed by intervals of no drug delivery. This approach helps to prevent sustained high drug concentrations in the bloodstream, reducing the risk of adverse effects associated with prolonged exposure. Unlike continuous infusion, steady-state concentrations may not be achieved during a single dosing cycle but can be reached through repeated...
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...